Coenzyme M
Accession Number
Small Molecule
Approved, Investigational

Coenzyme M (commonly known by its salt form, Mesna) is a synthetic sulfhydryl (thiol) compound and is used for prophylaxis of Ifosfamide and cyclophosphamide induced hemorrhagic cystitis.2

  • 2-Mercaptoethane
  • 2-Mercaptoethanesulfonate
  • 2-mercaptoethanesulfonic acid
  • 2-mercaptoethanesulphonic acid
  • 2-mercaptoethylsulfonate
  • 2-sulfanylethylsulfonate
  • Coenzima M
  • Coenzym M
  • CoM
  • HS-CoM
  • reduced coenzyme M
  • reduced CoM
  • β-mercaptoethanesulfonic acid
Product Ingredients
IngredientUNIICASInChI Key
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MesnaInjection, solution100 mg/1mLIntravenousBaxter Healthcare Corporation1988-12-30Not applicableUs
MesnaInjection, solution100 mg/1mLIntravenousBaxter Healthcare Corporation1988-12-30Not applicableUs
Mesna for InjectionSolutionIntravenousFresenius Kabi2002-08-22Not applicableCanada
MesnexTablet, film coated400 mg/1OralBaxter Healthcare Corporation2002-03-21Not applicableUs
MesnexInjection, solution100 mg/1mLIntravenousBaxter Healthcare Corporation1988-12-30Not applicableUs
UromitexanSolutionIntravenousBaxter Laboratories2012-04-13Not applicableCanada
UromitexanSolutionIntravenous; OralBaxter Laboratories2001-03-06Not applicableCanada
Uromitexan Inj 100mg/mlLiquidIntravenous; OralBristol Labs Division Of Bristol Myers Squibb1989-12-312001-06-12Canada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MesnaInjection, solution100 mg/1mLIntravenousTeva Parenteral Medicines, Inc.2002-05-012020-10-31Us
MesnaSolution100 mg/1mLIntravenousGland Pharma Limited2017-12-20Not applicableUs
MesnaInjection, solution100 mg/1mLIntravenousAlvogen Inc.2018-03-29Not applicableUs
MesnaInjection, solution100 mg/1mLIntravenousAGILA SPECIALTIES PRIVATE LIMITED2014-07-192017-09-01Us
MesnaInjection, solution100 mg/1mLIntravenousSagent Pharmaceuticals2013-04-30Not applicableUs
MesnaInjection, solution100 mg/1mLIntravenousFresenius Kabi USA, LLC2001-09-05Not applicableUs
MesnaInjection, solution100 mg/1mLIntravenousBedford Pharmaceuticals2008-03-032012-07-31Us
MesnaInjection, solution100 mg/1mLIntravenousBedford Pharmaceuticals2004-01-092012-07-31Us
MesnaInjection, solution100 mg/1mLIntravenousAthenex Pharmaceutical Division, Llc.2018-02-28Not applicableUs
MesnaInjection, solution100 mg/1mLIntravenousMylan Institutional2012-04-032016-09-30Us
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
IFEX and MESNEXMesna (100 mg/1mL) + Ifosfamide (3 g/60mL)KitIntravenousE.R. Squibb & Sons, L.L.C.2009-06-012010-03-31Us
IFEX and MESNEXMesna (100 mg/1mL) + Ifosfamide (1 g/20mL)KitIntravenousE.R. Squibb & Sons, L.L.C.2009-06-012010-06-30Us
IFEX and MESNEXMesna (100 mg/1mL) + Ifosfamide (1 g/20mL)KitIntravenousE.R. Squibb & Sons, L.L.C.2009-06-012010-06-30Us
Ifosfamide and MesnaMesna (100 mg/1mL) + Ifosfamide (1 g/20mL)KitIntravenousTeva Parenteral Medicines, Inc.2012-09-262012-09-26Us
Ifosfamide and MesnaMesna (100 mg/1mL) + Ifosfamide (1 g/20mL)KitIntravenousTeva Parenteral Medicines, Inc.2002-05-012011-07-31Us
Ifosfamide and MesnaMesna (100 mg/1mL) + Ifosfamide (3 g/60mL)KitIntravenousTeva Parenteral Medicines, Inc.2012-09-262012-09-26Us
International/Other Brands
Mistabron / Mistabronco
CAS number
Average: 142.197
Monoisotopic: 141.975835438
Chemical Formula
InChI Key
2-sulfanylethane-1-sulfonic acid



Mesna is a uroprotective agent and is used prophylactically to reduce ifosfamide and cyclophosphamide induced hemorrhagic cystitis.2

Associated Conditions

Mesna binds to and inactivates acrolein there by preventing or reducing bladder problems

Mechanism of action

A metabolite called acrolein is produced when ifosfamide and cyclophosphamide are metabolized. This metabolite concentrates in the bladder and causes cell death via upregulation of reactive oxygen species (ROS), and activates inducible nitric oxide synthase (iNOS) which leads to production of nitric oxide (NO). Both ROS and NO produce products which are detrimental to lipids, proteins and DNA strands. Furthermore, ROS stimulate gene expression of pro-inflammatory cytokines such as TNF-α AND IL-1β. Acrolein may also lead to ulceration of the bladder urothelium. Mesna protects against cyclophosphamide and ifosfamide induced hemorrhagic cystitis by binding to their toxic metabolites. Mesna is metabolized to dimesna and excreted by the kidneys. Glutathione dihydrogenase acts on the reabsorbed portion and produces free sulfhydryl groups. These free sulfhydryl groups bind acrolein in the bladder, allowing effective excretion and prevention of toxic effects.1 In addition, Mesna binds to and detoxifies a urotoxic ifosfamide metabolite called 4-hydroxy-ifosfamide.

Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more

Peak plasma concentrations were reached within 1.5-4 hours for free mesna, and 3-7 hours for total mesna following oral administration. The average oral bioavailability is 58% for free mesna and 89% for total mesna. Food has no effect on the urinary availability of mesna.

Volume of distribution

Vd = 0.652 ± 0.242 L/Kg after intravenous administration of mesna.

Protein binding

Total plasma mesna is 28% protein bound.3


Mesna undergoes rapid oxidation to mesna disulfide (dimesna) which is its major metabolite.

Route of elimination

Within 24 hours, approximately 32% of administered dose is eliminated in the urine as mesna while 33% is eliminated as dimesna.

Half life

The elimination half-life is 0.36 hours for mesna and 1.17 hours for dimesna.


Plasma clearance of mesna = 1.23 L/h/kg


The following adverse events were most common (>10%) when mesna was administered with ifosfamide: nausea, vomiting, fatigue, fever, abdominal pain, constipation, diarrhea, leukopenia, anorexia, thrombocytopenia, anemia, granulocytopenia, asthenia, headache, alopecia, and somnolence. Hypersensitivity reactions and dermatologic toxicity may occur in patients taking mesna; therefore, if either reaction occurs, mesna should be discontinued and patient should be provided with supportive care.

Affected organisms
Not Available
Not Available
Pharmacogenomic Effects/ADRs
Not Available


Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available


General References
  1. Matz EL, Hsieh MH: Review of Advances in Uroprotective Agents for Cyclophosphamide and Ifosfamide-Induced Hemorrhagic Cystitis. Urology. 2016 Aug 23. pii: S0090-4295(16)30458-7. doi: 10.1016/j.urology.2016.07.030. [PubMed:27566144]
  2. Cutler MJ, Urquhart BL, Velenosi TJ, Meyer Zu Schwabedissen HE, Dresser GK, Leake BF, Tirona RG, Kim RB, Freeman DJ: In vitro and in vivo assessment of renal drug transporters in the disposition of mesna and dimesna. J Clin Pharmacol. 2012 Apr;52(4):530-42. doi: 10.1177/0091270011400414. Epub 2011 Apr 19. [PubMed:21505084]
  3. DynaMed [Link]
External Links
Human Metabolome Database
KEGG Compound
PubChem Compound
PubChem Substance
PDBe Ligand
RxList Drug Page Drug Page
PDRhealth Drug Page
ATC Codes
R05CB05 — MesnaV03AF01 — Mesna
AHFS Codes
  • 92:56.00 — Protective Agents
PDB Entries
1e6v / 1e6y / 1hbn / 1hbo / 1hbu / 1mro / 2c3c / 2c3d / 3m1v / 3m2r
show 25 more
FDA label
Download (3.61 MB)

Clinical Trials

Clinical Trials
0CompletedTreatmentPrecursor Cell Lymphoblastic Leukemia-Lymphoma1
1CompletedTreatmentAgnogenic Myeloid Metaplasia / Leukemias / Malignant Lymphomas / Smith-Magenis Syndrome1
1CompletedTreatmentJuvenile Myelomonocytic Leukemia Lymphoblastic / Leukemia Acute Myeloid Leukemia (AML) / Leukemia, Lymphocytic, Acute, T-Cell / Myelodysplastic Syndrome / T-cell Lymphoblastic Lymphoma1
1CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1CompletedTreatmentLymphoma, Hodgkins / Malignant Lymphomas1
1CompletedTreatmentSclerosis, Progressive Systemic1
1CompletedTreatmentSoft Tissue Sarcoma (STS)1
1Not Yet RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1RecruitingTreatmentAgnogenic Myeloid Metaplasia / Hematological Diseases / Immune Deficiencies / Malignant Lymphomas / Multiple Myeloma (MM) / Tumors, Solid1
1RecruitingTreatmentAplastic Anemia / Chronic Leukemias / Congenital Hematological Disorder / Immune Deficiency Disorder / Leukemia, Acute / Malignant Lymphomas / Metabolism Disorder / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Tumors, Solid1
1TerminatedTreatmentBrain and Central Nervous System Tumors / Liver Cancer / Renal Cancers / Retinoblastoma / Sarcomas1
1TerminatedTreatmentLeukemias / Malignant Lymphomas / Plasma Cell Myeloma1
1TerminatedTreatmentLung Cancer Metastatic / Sarcoma, Osteogenic1
1TerminatedTreatmentMyasthenia Gravis1
1TerminatedTreatmentNeoplasms, Kidney1
1, 2Active Not RecruitingTreatmentStiff Person Syndrome / Stiff-Person Syndrome1
1, 2CompletedTreatmentAcute Lymphocytic Leukemia (ALL) / Leukemias1
1, 2CompletedTreatmentBreast Cancer1
1, 2CompletedTreatmentLymphoma, Hodgkins1
1, 2CompletedTreatmentMalignancies, Hematologic1
1, 2CompletedTreatmentMalignant Lymphomas1
1, 2CompletedTreatmentNeuromyelitis Optica1
1, 2CompletedTreatmentSarcomas1
1, 2Not Yet RecruitingTreatmentCrohn's Disease (CD)1
1, 2RecruitingTreatmentAcute Lymphoblastic Leukemia, in Relapse / Refractory Acute Lymphoblastic Leukemia1
1, 2RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / B-lymphoid Malignancies / Chronic Lymphocytic Leukaemia (CLL) / Non-Hodgkin's Lymphoma (NHL)1
1, 2RecruitingTreatmentCrohn's Disease (CD)1
1, 2RecruitingTreatmentTransplantation, Liver1
1, 2TerminatedTreatmentMetastatic Cancers1
1, 2TerminatedTreatmentNeoplasm Metastases / Neoplasms, Breast1
1, 2Unknown StatusTreatmentBreast Cancer2
1, 2WithdrawnTreatmentLymphoma, Hodgkins / Malignant Lymphomas / Non-Hodgkin's Lymphoma (NHL)1
1, 2WithdrawnTreatmentTransplantation, Liver1
2Active Not RecruitingTreatmentAcute Biphenotypic Leukemia (ABL) / Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma / Acute Undifferentiated Leukemia (AUL) / Chemotherapy-sensitive Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS)1
2Active Not RecruitingTreatmentAdvanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma / Non-Hodgkin's Lymphoma (NHL)1
2Active Not RecruitingTreatmentBone Marrow Failure Syndromes / Severe Aplastic Anemia (SAA)1
2Active Not RecruitingTreatmentBreast Cancer1
2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Lymphoma, Hodgkins / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Lymphoma, Low-Grade / Mantle Cell Lymphoma (MCL) / Small Lymphocytic Lymphoma / T-cell type lymphoma1
2Active Not RecruitingTreatmentGerm Cell Tumors1
2Active Not RecruitingTreatmentLeukemias1
2Active Not RecruitingTreatmentLeukemias / Malignant Lymphomas1
2Active Not RecruitingTreatmentMalignant Lymphomas / Mantle Cell Lymphoma (MCL)1
2Active Not RecruitingTreatmentNeoplasms, Brain / Tumors of the Central Nervous System1
2Active Not RecruitingTreatmentNeuroblastomas1
2Active Not RecruitingTreatmentTesticular Cancer1
2CompletedPreventionContrast Media Exposition / Renal Insufficiency,Chronic / Serum Creatinine Concentration1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias1
2CompletedTreatmentAplastic Anemia1
2CompletedTreatmentB-Cell Non-Hodgkin Lymphomas(NHL) / Malignant Lymphomas1
2CompletedTreatmentBlood Stem Cell Transplant Failure / Leukemias / Malignancies, Hematologic1
2CompletedTreatmentBreast Cancer1
2CompletedTreatmentBreast Cancer / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentChronic Myeloid Leukemia (CML) / Leukemia, Lymphocytic, Acute / Leukemia, Myelocytic, Acute / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentDisseminated Sclerosis1
2CompletedTreatmentEnd Stage Renal Disease (ESRD)1
2CompletedTreatmentEwing's Sarcoma (ES) / Neuroblastomas / Non-rhabdomyosarcoma Soft Tissue Sarcomas / Non-rhabdomyosarcoma Soft-tissue Sarcoma1
2CompletedTreatmentLeukemias / Malignant Lymphomas1
2CompletedTreatmentLeukemias / Malignant Lymphomas / Transplantation, Stem Cell1
2CompletedTreatmentMalignant Lymphomas7
2CompletedTreatmentMalignant Lymphomas / Mantle Cell Lymphoma (MCL)1
2CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentSystemic Lupus Erythematosus (SLE)1
2RecruitingSupportive CareLocally Advanced Sarcoma / Sarcomas1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Chronic Myeloid Leukemia (CML) / Granulocytic Sarcoma / Juvenile Myelomonocytic Leukemia (JMML) / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS) / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Chronic Myeloid Leukemia (CML) / Juvenile Myelomonocytic Leukemia (JMML) / Leukemia Acute Myeloid Leukemia (AML) / Lymphoma, Hodgkins / Myelodysplastic Syndromes (MDS) / NK-Cell Leukemia / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentChildhood Germ Cell Tumor / Ovarian Cancer / Teratoma1
2RecruitingTreatmentDiffuse Sclerosis Systemic / Interstitial Lung Diseases (ILD) / Pulmonary Hypertension (PH) / Sclerosis, Progressive Systemic1
2RecruitingTreatmentEffects of Chemotherapy / Lung Cancer Non-Small Cell Cancer (NSCLC)1
2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2RecruitingTreatmentMalignant Lymphomas2
2RecruitingTreatmentNewly Diagnosed Ewing Sarcoma1
2RecruitingTreatmentSickle Cell Disorders1
2TerminatedTreatmentAtypical Burkitt Lymphoma / Burkitt's Lymphoma / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentHaematological Malignancies1
2TerminatedTreatmentLeukemias / Pediatric Cancer1
2TerminatedTreatmentMedulloblastomas / Neoplasms, Brain / Primitive Neuroectodermal Tumor / Tumors of the Central Nervous System1
2TerminatedTreatmentTransplantation, Kidney1
2WithdrawnTreatmentB-cell Adult Acute Lymphoblastic Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia1
2WithdrawnTreatmentCrohn's Disease (CD)2
2WithdrawnTreatmentFibrolamellar Hepatocellular Carcinoma / Hepatocellular Carcinoma (Fibrolamellar Variant) / Hepatocellular,Carcinoma1
2, 3Active Not RecruitingTreatmentMultiple Myeloma (MM)1
2, 3Active Not RecruitingTreatmentScleroderma / Sclerosis, Progressive Systemic1
2, 3WithdrawnTreatmentAcute Renal Failure (ARF)1
2, 3WithdrawnTreatmentNeuromyelitis Optica / NMO Spectrum Disorder1
3Active Not RecruitingTreatmentRelapsing Remitting Multiple Sclerosis (RRMS)1
3Active Not RecruitingTreatmentScleroderma / Scleroderma, Systemic1
3CompletedTreatmentBreast Cancer1
3CompletedTreatmentLung Cancers1
3CompletedTreatmentLymphoma, Large-Cell, Diffuse1
3CompletedTreatmentMalignant Lymphomas1
3CompletedTreatmentNeoplasms, Brain / Tumors of the Central Nervous System1
3Unknown StatusTreatmentLeukemias1
3Unknown StatusTreatmentSarcomas1
4CompletedTreatmentMultiple Myeloma (MM)1
4Not Yet RecruitingTreatmentPleural Effusions1
4RecruitingTreatmentNasal and Nasal-type NK/T-cell Lymphoma1
Not AvailableActive Not RecruitingTreatmentDisseminated Neuroblastoma / Localized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Regional Neuroblastoma / Stage 4S Neuroblastoma1
Not AvailableCompletedSupportive CareNausea / Sarcomas / Vomiting1
Not AvailableCompletedTreatmentAdverse Effects of Medical Drugs / Chemotherapy-Induced Nausea and Vomiting (CINV) / Effects of Chemotherapy / Sarcomas1
Not AvailableCompletedTreatmentChildhood Germ Cell Tumor / Extragonadal Germ Cell Tumor1
Not AvailableCompletedTreatmentMalignant Lymphomas1
Not AvailableRecruitingTreatmentAtypical Teratoid/Rhabdoid Tumor (AT/RT) / Ewing's Family Tumors / Germ Cell Tumors / Hepatoblastomas / Medulloblastomas / Primary Malignant Brain Neoplasms / Renal Tumors / Retinoblastoma / Rhabdomyosarcomas / Soft Tissue Sarcoma (STS) / Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET) / Tumors of the Central Nervous System1
Not AvailableRecruitingTreatmentBare Lymphocyte Syndrome / CD40 Ligand Deficiency / Chediak-Higashi Syndrome / Chronic Granulomatous Disease (CGD) / Common Variable Immunodeficiency / Griscelli Syndrome / Hyper IgM Syndrome / Langerhan's Cell Histiocytosis / Lymphohistiocytosis, Hemophagocytic / Omenn's Syndrome / Reticular Dysgenesis / SCID / Wiskott-Aldrich Syndrome (WAS) / X-Linked Lymphoproliferative Disease1
Not AvailableRecruitingTreatmentHaemoglobinopathies congenital / Sickle Cell Disorders1
Not AvailableRecruitingTreatmentMalignancies, Hematologic1
Not AvailableSuspendedTreatmentMedulloblastomas1
Not AvailableTerminatedTreatmentHemoglobin SC / Sickle Cell Disorders1
Not AvailableTerminatedTreatmentImplant Capsular Contracture1
Not AvailableTerminatedTreatmentLeukemias / Lymphoma, Hodgkins / Malignancies / Malignant Lymphomas / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableTerminatedTreatmentLeukemias / Lymphoma, Hodgkins / Myeloproliferative Disorders / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableTerminatedTreatmentSarcoma, Osteogenic1
Not AvailableTerminatedTreatmentThalassaemic disorders1
Not AvailableUnknown StatusNot AvailableSmall Cell Lung Cancer (SCLC)1


Not Available
Not Available
Dosage forms
Injection, solutionIntravenous100 mg/1mL
SolutionIntravenous100 mg/1mL
Tablet, film coatedOral400 mg/1
SolutionIntravenous; Oral
LiquidIntravenous; Oral
Not Available
Not Available


Experimental Properties
Not Available
Predicted Properties
Water Solubility12.7 mg/mLALOGPS
pKa (Strongest Acidic)-1.2ChemAxon
pKa (Strongest Basic)-9.6ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area54.37 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity29.13 m3·mol-1ChemAxon
Polarizability12.54 Å3ChemAxon
Number of Rings0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available


Mass Spec (NIST)
Not Available
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-MS (2 TMS)GC-MSsplash10-00e9-7960000000-d0e9fc5f5629ba893d57
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - GC-MSGC-MSsplash10-00e9-7960000000-d0e9fc5f5629ba893d57
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-052u-2900000000-51cd7c5f2497db0c7a15
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-004m-7970000000-a5c3c33a78b251bdd12c
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-001i-9400000000-f69174f630c88b6e6c0b


This compound belongs to the class of organic compounds known as organosulfonic acids. These are compounds containing the sulfonic acid group, which has the general structure RS(=O)2OH (R is not a hydrogen atom).
Organic compounds
Super Class
Organic acids and derivatives
Organic sulfonic acids and derivatives
Sub Class
Organosulfonic acids and derivatives
Direct Parent
Organosulfonic acids
Alternative Parents
Sulfonyls / Alkanesulfonic acids / Alkylthiols / Organic oxides / Hydrocarbon derivatives
Alkanesulfonic acid / Sulfonyl / Organosulfonic acid / Alkylthiol / Organic oxygen compound / Organic oxide / Hydrocarbon derivative / Organosulfur compound / Aliphatic acyclic compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
thiol, organosulfonic acid (CHEBI:17905)


Pharmacological action
General Function
Nadp binding
Specific Function
Maintains high levels of reduced glutathione in the cytosol.
Gene Name
Uniprot ID
Uniprot Name
Glutathione reductase, mitochondrial
Molecular Weight
56256.565 Da
  1. Ormstad K, Orrenius S, Lastbom T, Uehara N, Pohl J, Stekar J, Brock N: Pharmacokinetics and metabolism of sodium 2-mercaptoethanesulfonate in the rat. Cancer Res. 1983 Jan;43(1):333-8. [PubMed:6401168]

Drug created on September 17, 2015 15:16 / Updated on April 06, 2020 22:21

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.